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Abstract 
Background: Human immunodeficiency virus (HIV) Rapid diagnostic Test (RDT) kits are the preferred assays for HIV 
testing in many countries. Prevention of Mother-to-Child Transmission, Know Your Status Campaigns, Blood-Safety, 
Voluntary Counseling and Testing are major strategies adapted to control transmission of the virus and the pivot of 
these interventions is either screening or diagnosing individuals through testing. There are reports of inconsistent 
sensitivity and specificity with whole blood and serum samples collected from the same individual. Little is known 
about the diagnostic characteristics of First Response HIV-1-2 RDT kit, used as a single test kit in national HIV preven-
tion and control programmes. The debate has always centered on choosing between whole blood and serum in a 
case where a single test kit that runs on only blood specimen will be used for testing. The variations in specificities 
and sensitivities with whole blood and serum samples imply that some individuals who might be true positives will 
be missed and elude care. This study determined the best blood-based specimen type (whole blood or serum) that 
improves performance of First Response HIV RDT kit in detecting HIV-specific antibodies.
Methods: A hospital-based cross-sectional study was conducted on 280 HIV infected and non-infected patients from 
May 2015 to June 2015. Blood samples from each participant were separated into whole blood and serum, and tested 
on First Response HIV-1-2 kits (Premier Medical Corporation Ltd., Kachigam, India) using Electro-chemi-luminescence 
assay (ECLIA) as reference assay.
Results: First Response HIV-1-2 RDT kit showed 100 % sensitivity and 100 % specificity with whole blood specimen 
and 100 % sensitivity and 82.86 % specificity with serum specimen for the detection of HIV-1. The positive and nega-
tive predictive values were 100, 100 and 85.35, 82.86 % for whole blood and serum respectively.
Conclusion: Whole blood specimen(s) from an individual have higher specificity, positive and negative predictive 
values than serum. Whole blood is the primary specimen to use on First Response HIV-1-2 RDT kit when screening 
peripheral blood for HIV-1-specific antibodies.
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Background
Diagnosing Human Immuno-deficiency Virus (HIV) 
infection at the early stages is instrumental in HIV/
AIDS disease surveillance. Technologies that allow the 
detection of very low levels of HIV nucleic acids (RNA 
or DNA), viral p24 antigens, and HIV-specific antibod-
ies have been developed [1]. In spite of these successes, 
laboratory assays in general are still imperfect, and some 
recent infections remain undetected [2]. Viral load test, 
the gold standard, can identify 96 % of recent infections. 
The fourth generation Enzyme Immuno Assays (EIAs) 
identify 93 % and the third generation EIAs [Rapid Diag-
nostic Test (RDT) kits] (also identify) 63 % of all recent 
infections [3]. Although RDT kits have the lowest detec-
tion ability, they remain the preferred assay for HIV test-
ing in many countries. This is because they require little 
expertise to use, run on little sample volumes, cheaper in 
cost and produce test results in 15  min [4]. The perfor-
mance of HIV RDT kits differ with brand(s) [5], there-
fore, are used in combination to improve diagnosis [6]. 
Ghana has adopted the serial testing algorithm where 
First Response HIV-1-2 kit (Premier Medical Corpora-
tion Ltd., Kachigam, India) is used to screen samples 
and Oraquick Advance HIV-1-2 kit (OraSure Technolo-
gies, Bethlehem, PA, USA) is primarily used to confirm 
infection. Nonetheless, First Response HIV-1-2 kit is 
often used as a single test kit in national HIV prevention 
and control programmes. A study by Laperche et al. [7], 
linked the practice of single RDT kit use (for screening 
test samples) to high HIV infection rates. In that study, 
single RDT kit use detected 85 % of infections that were 
detectable by standard Enzyme Linked Immuno-Sorbent 
Assay (ELISA) [7]. In other words, 15  % HIV infected 
individuals were not detected when a single RDT kit was 
used to screen the population. The results were similar 
when the test specimen was either whole blood or serum.
Blood specimen (whole blood, plasma or serum) is the 
sample to apply on First Response HIV-1-2 RDT kit. Field 
reports indicate that blood specimen contains unequal 
concentrations of detectable HIV-specific antibodies 
in whole blood and serum. Sensitivity and specificity of 
HIV rapid test kits differ with whole blood (95  %) and 
serum specimens (98 %) [6, 8]. Better specificity (99.9 %) 
is achieved with whole blood than using serum specimen 
(99 %) [9]. One may argue that it is better to use highly 
sensitive samples (serum) for testing. Conversely, a field 
study found serum samples to produce more false nega-
tive results compared to whole blood samples [10]. This 
loss of sensitivity is important especially in resource 
limited settings where RDTs are widely used. A study 
in Cape Town, South Africa, recorded 1100 HIV posi-
tive cases that were initially diagnosed negative due to 
poor RDT sensitivity [5]. Other studies conducted in 
sub-Saharan Africa reported that 3 % of people undergo-
ing HIV testing at out-patient departments are at risk of 
receiving false negative results and recommended a fol-
low-up post-transfusion HIV testing for blood recipients 
to monitor sero-conversion [11, 12].
The concern of the authors suggests that the test speci-
men and/or kit used to screen blood prior to donation 
might have missed possible positive cases.
Owusu-ofori et al. [13], proposed that Ghana comple-
ment serologic rapid test with Nucleic Acid Test (NAT) 
in pre-donation screening of blood donors. Neverthe-
less, NAT comes with a lot of technical and economic 
constraints. This leaves the country in equipoise since 
studies on the affordable HIV RDT kits are reporting 
varying sensitivity and specificity with test specimen 
types. The evidence from these studies suggests a need 
to assess HIV RDT kits used in specific settings to deter-
mine the blood-based specimen type that improves per-
formance. The dilemma now is deciding between whole 
blood and serum in cases where single test kits are used 
for testing.
In Ghana, depending on the setting where the test is 
performed, either whole blood or serum sample is used 
on the First Response HIV-1-2 kit. What is not known 
is whether the test kit produces consistent results with 
these specimens and there have not been any inde-
pendent post-market assessment studies to ascertain 
the comparability of the kit using the different blood-
based specimens. This study assessed the First Response 
HIV-1-2 kit using whole blood and serum samples 




In this study, we did not detect HIV-2 among the sam-
ples tested. 280 out of the 295 (94.9 %) samples collected 
were accurately classified. All 140 (50  %) samples col-
lected from already diagnosed patients under treatment 
tested positive for HIV-1. 2 OPD and three prospective 
blood donor samples were positive for HIV-1 but they 
were excluded from the analysis. The OPD patients were 
referred to the ART centre for counseling to commence 
treatment. The decision on the blood donors was referred 
to the Regional Blood Service.
140 (50 %) samples were negative for HIV after testing. 
100 were collected from prospective blood donors and 40 
from OPD patients. 35 (12.5  %) samples produced dis-
cordant results.
25 out of the 35 discordant samples (71.43  %) 
were classified as negative according to the criterion 
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described later. These samples produced non-reactive 
results for both whole blood and serum on the test kit 
and non-reactive serum result on the analyzer (ECLIA). 
10 samples out of the 35 discordant samples (28.57  %) 
produced discordant results after repeated tests and 
could not be classified. They were excluded from the 
analysis.
Proportion of HIV‑1 infected and non‑infected people 
testing positive or negative with serum on First Response 
HIV‑1‑2 RDT kit and ECLIA
First Response HIV-1-2 RDT kit accurately identified all 
140 HIV-1 infected samples as positive when serum was 
used as the test specimen. The test kit achieved compa-
rable sensitivity (100  %) with ECLIA. The kit’s positive 
predictive value using serum as test specimen was 100 % 
(Table  1). 116 of the 140 HIV-1 non-infected samples 
tested negative using serum as test specimen on First 
Response HIV-1-2 kit. 24 samples tested positive (false 
positive) and did not agree with the negative results 
obtained from ECLIA. The specificity of the test kit was 
82.86 % and was significantly lower compared to ECLIA 
(100 %) as depicted in Table 2.
Proportion of HIV‑1 infected and non‑infected people 
testing positive or negative with whole blood on First 
Response HIV‑1‑2 kit and ECLIA
Using whole blood as test specimen, First Response HIV-
1-2 RDT kit accurately detected all 140 HIV-1 positive 
samples collected from 140 HIV-1 infected people. The 
kit was 100 % sensitive and 100 % positive prediction in 
detecting HIV-1 that agreed with ECLIA (Table 3). This 
was not contrary to what was indicated on the test kit 
(99.8 %).
All the 140 HIV non-infected samples that tested nega-
tive on First Response HIV-1-2 RDT kit using whole 
blood as test specimen agreed with the ECLIA results. 
The test kit was as good as ECLIA showing 100  % for 
specificity and negative predictive value (Table 4).
Proportion of HIV infected and non‑infected people testing 
positive or negative with serum or whole blood on First 
Response HIV‑1‑2 RDT kit compared to ECLIA
Overall, First Response HIV-1-2 RDT kit detected HIV-1 
antibodies in 164 of the 280 samples collected from both 
HIV-1 positive and negative patients as positive with 
serum specimen (Table 5). 116 of the 280 samples were 
Table 1 Sensitivity, positive predictive value (PPV) of assays with serum specimen
Test (assay) No. of HIV‑1 positive  
samples
Positive serum  
results
False negative  
result
Sensitivity (%) PPV (%)
First response HIV-1-2 kit 140 140 0 100 100
ECLIA (reference) 140 140 0 100 100
Table 2 Specificity, negative predictive value (NPV) of assays with serum specimen




False positive  
result
Specificity (%) NPV (%) P value
First response HIV-1-2 kit 140 116 24 82.86 82.86 <0.001
ECLIA (reference) 140 140 0 100 100
Table 3 Sensitivity, positive predictive value (PPV) of assays with whole blood specimen
Test (assay) No. of HIV‑1 positive  
samples
Positive whole blood  
results
False negative  
result
Sensitivity (%) PPV (%)
First response HIV-1-2 kit 140 140 0 100 100
ECLIA (reference) 140 140 0 100 100
Table 4 Specificity, negative predictive value (NPV) of assays with whole blood specimen
Test (assay) No. of HIV‑1 positive 
samples
Negative whole blood  
results
False positive  
result
Specificity (%) NPV (%)
First response HIV-1-2 kit 140 140 0 100 100
ECLIA (reference) 140 140 0 100 100
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identified as negative with serum specimen (Table 5). 140 
HIV-1 positive samples were detected as positive and 140 
samples were identified as negative using whole blood 
as test specimen on First Response HIV-1-2 RDT kit 
(Table 5). ECLIA detected 140 of the 280 samples as posi-
tive and 140 as negative. 24 false positives results were 
produced with serum specimen. ECLIA demonstrated 
100 % sensitivity and specificity, and 100 % positive and 
negative predictions (Table 5).
First Response HIV-1-2 RDT kit showed the same 
sensitivity (100  %) as ECLIA with both whole blood 
and serum specimens but significantly lower specificity 
(82.86 %) with serum specimen (p < 0.001). The predic-
tive values were also significantly lower with serum spec-
imen compared to whole blood and ECLIA for positivity 
(85.37 %) and negativity (82.86 %) (p < 0.001). All the pos-
itive results showed strong reactive bands and there were 
no weak reactive results (Table 5).
Discussion
Collectively, First Response HIV-1-2 RDT kit showed 
100  % sensitivity for the detection of HIV-1 with both 
serum and whole blood specimens, 100 % specificity with 
whole blood and these results completely agreed with 
those of ECLIA. Yet, the high number of False Positives 
(25) observed with serum specimen on the test kit was 
contrary to ECLIA and resulted in a lower Positive and 
Negative Predictive Values (85.37  %) (82.86  %) respec-
tively. These results were consistent with Anzala et  al. 
[14] who assessed Rapid Diagnostic Test (RDT) kits used 
for counseling and testing in Kenya and Uganda.
Positive Predictive Value (PPV) is the proportion of 
patients with a positive test who actually have the dis-
ease. Negative Predictive Value (NPV) is the proportion 
of patients with a negative test who do not have the dis-
ease. One way to avoid confusing this with sensitivity 
and specificity is to imagine that you are a patient and 
you have just received the results of your screening test. 
If the test was positive, then what is the probability that 
‘you’ the patient really have the disease (Positive Predic-
tion), that is how worried should you be? Conversely, if 
it is good news, and the screening test was negative, how 
reassured should you be? Thus the probability that you 
are disease free? (Negative Prediction).
Generally, the performance of HIV rapid diagnostic 
testing in a population is influenced by Positive and 
Negative Predictive values of the RDT kits used. Thus 
sensitivity and specificity results obtained from test kit 
evaluation studies (quoted in manufacturer’s instruc-
tion manuals) prior to licensing and marketing of the 
kit will not necessarily be achieved in practice. Predic-
tive values vary among populations such that PPV and 
NPV of HIV RDT kits are lower in low HIV prevalent 
areas like Ghana (1.3  %) [15]. In this study a PPV of 
85.37  % was recorded with serum specimen explain-
ing the higher False Positives and the lower negative 
prediction of the test kit compared to ECLIA. This 
suggests that ~15  % of people who test with serum 
specimen on First Response HIV-1-2 RDT kit in such 
study settings with similar characteristics as Ghana 
will receive False Positive results. Among the positive 
samples tested, both whole blood and serum showed 
similar PPVs (100 %) as ECLIA. This suggests however, 
that First Response HIV-1-2 RDT kit is well designed 
to detect HIV-1 antibodies in blood specimen if they 
so contain any. Never the less, the lower specificity 
(82.86 %) expressed by the RDT kit indicates the occur-
rence of high cross-reactivity when serum is used as 
the test specimen. Serum specimens are known to con-
tain various antibodies that may bind to reaction sites 
(epitopes) meant for target antibodies [16]. Therefore, 
First Response HIV-1-2 RDT kits may present the chal-
lenge of high antibody cross-reactivity with serum 
specimen than whole blood. Hence, serum specimen 
may not accurately predict the presence or absence of 
HIV-1-specific antibodies in the blood. The increased 
PPV and NPV with whole blood in the current study 
may imply that the lower performance of the test kit 
observed under serum could be improved with whole 
blood specimens. Accordingly, a second test kit of 
higher specificity may not be needed to confirm serum 
results on First Response HIV-1-2 RDT kit as recom-
mended by Parekh et  al. [15]. In the case of Ghana, 
this will save cost, and the more expensive and scarce 
OraQuick Advanced HIV-1-2 RDT kits may not be 
fast needed to confirm initially screened serum results. 
Alternatively, samples may be screened first with whole 
blood instead of serum on First Response HIV-1-2 RDT 
Table 5 Sensitivity, specificity, positive and negative predictive values of First response HIV-1-2 kit compared to ECLIA
Test‑type and  
specimen
















Whole blood 140 140 0 0 280 100 100 100 100
Serum 164 116 24 0 280 100 82.86 85.37 82.86 <0.001
ECLIA (reference) 140 140 0 0 280 100 100 100 100
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kit and reactive ones confirmed on OraQuick Advance 
HIV-1-2 RDT kit to minimize wastage of the later.
Although the comparable sensitivity and PPV results 
(100  %) achieved with First Response HIV-1-2 RDT kit 
in the current study using whole blood differed in abso-
lute percentages from Kroidl et al. [10] (99.5 %) yet were 
consistent with those reported by the manufacturer 
(100 %). Moreover, this study tested whole blood samples 
collected from low HIV prevalent populations whereas 
Kroidl et  al., 2012, sampled the blood from high preva-
lent populations. This gives a hint to better use whole 
blood on First Response HIV-1-2 RDT kit in both low 
and high HIV prevalent populations. Even though the 
higher Positive Predictive Value and zero False Posi-
tive results achieved with whole blood specimen in this 
study were contrary to what was reported by Bi et  al. 
[17]; the two studies differ in certain respect. Whereas 
First Response HIV-1-2 RDT kit was used in the current 
study, OraQuick Advance HIV-1-2 RDT kit was assessed 
in theirs. Notwithstanding, it has been documented by 
Moal et al. [6] that HIV RDT kits from different manu-
facturers vary in sensitivity and specificity. Providing 
grounds to infer that the technologies used to design 
these kits may also differ hence would not yield parallel 
results with similar test specimen.
Limitations and strengths of the study
The present study is limited in various ways, and that the 
results should be interpreted with caution. Commercial 
ELISA that has been fully described in the study setting 
was not used as the reference test. There were no docu-
ments in the current setting that compared the HIV 
diagnostic performance of ECLIA to commercial ELISA. 
Nonetheless, the diagnostic successes of ECLIA over 
commercial ELISA [17] cannot be ignored.
This study is one of the few that assessed HIV RDT kits 
against ECLIA [17, 18] and the only one that had com-
pared First Response HIV-1-2 RDT kit to ECLIA. Again, 
the False Positive results observed with serum specimen 
were not confirmed with PCR because of limited logistics 
and technical constraints.
Nevertheless, ECLIA is highly sensitive and specific 
and had performed well against PCR in diagnosing HIV 
infection in multiethnic regions [17]. Moreover, all the 
False Positive serum samples were negative with whole 
blood and this was consistent with ECLIA which also 
uses serum as test specimen. These results show the 
success of the exclusion criteria since many discrepant 
results were minimized.
Conclusion
Using serum as test specimen on First Response HIV-
1-2 RDT kit increases the tendency of producing false 
positive results. Whole blood specimens from individuals 
have higher specificity, and positive and negative predic-
tive values than serum. Whole blood is the primary spec-
imen to use on First Response HIV-1-2 RDT kit when 
screening peripheral blood for HIV-1-specific antibodies.
Recommendation
Whole blood specimen is excellent to use on First 
response HIV-1-2 RDT kit to screen populations in 
Ghana to detect HIV-1-specific antibodies. Whole blood 
should be preferred to serum specimen in blood banks 
to screen prospective donors. Settings that use serum as 
test specimen should adopt whole blood but must con-
firm all reactive results with standard confirmatory tests. 
Future studies should assess the diagnostic characteris-




The study was conducted in three different hospitals 
(Tamale Teaching Hospital, Tamale Central Hospital and 
Savelugu Municipal Hospital) in the northern region of 
Ghana.
Ethnicity
The main ethnic group in Tamale metropolis and 
Savelugu municipal is Dagomba. However other ethnic 
groups such as Akan, Frafras, Mamprusi, Moshe, Ewe, 
can be found in both the metropolis and the municipality 
[19].
Socio‑economic status
The major occupation(s) in these areas (Tamale Metropo-
lis and Savelugu municipality) are farming, craftsmanship 
and petty trading among women and men. A proportion 
of the population engages in public services, however, 
unemployment rate among the youth of the metropolis is 
high, reflecting the high poverty level in the metropolis.
Participants
Participants were recruited from the Out-Patient Depart-
ment (OPD), laboratory and Anti-Retro Viral Therapy 
(ART) centres of these hospitals. They involved: adult 
HIV patients (≥18 years) who had been on antiretroviral 
therapy for not more than 10 years; adult OPD patients 
(≥18  years) with positive or negative HIV results after 
laboratory testing; patients with normal haematologi-
cal and biochemical test results after laboratory analy-
sis; and prospective blood donors who tested either 
positive or negative for HIV, Hepatitis B, Hepatitis C and 
syphilis. In order to minimize false positive and nega-
tive results, all adult HIV patients (≥18  years) who had 
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received antiretroviral therapy for more than 10  years 
were excluded [11]. Also, all pregnant women who vis-
ited the facilities were not considered as participants for 
this study [14]. Additionally, children less than 18 months 
born to HIV positive mothers were not recruited [20].
Sample size calculation
The sample size (N) was calculated using the sen-
sitivity (100  %) and specificity (99.5  %) values 
quoted in the test kit manufacturer’s instruction 
package insert and the national HIV prevalence 




+ (1− prevalence) and NPV =
specificity ×(1−prevalence)
(1−sensitivity)×prevalence + specificity× (1− prevalence) to 
estimate the positive and negative predictive values of the 
test kit. The positive predictive value was 97  % and the 
negative predictive value was 100 %. This means there is a 
3 % probable positive case that will not be detected by the 
kit. The predictive values were computed in a sample size 
calculator to determine the sample size by the formula 
N  =  2 {10.5  ×  [PPV  ×  (100−NPV)  +  NPV  ×  (100−
PPV)/(PPV−NPV) ^2]} at a power of 80 % and a signifi-
cance level of 0.05. The sample size was 280 participants 
after correcting for non-respondents. 15 (5.08  %) par-
ticipants had incomplete data and were categorized as 
non-respondents.
Study design
A hospital-based cross-sectional study was conducted on 
HIV infected and non-infected patients from May 2015 
to June 2015. Whole blood and serum samples collected 
from these participants were tested on First Response 
HIV-1-2 RDT kit, and ECLIA technology was used as 
the gold standard assay. The test kit’s sensitivity, specific-
ity, positive and negative predictive values achieved with 
serum and whole blood specimens were determined and 
compared.
Testing procedures
Clinical samples collection, processing and storage
The specimens used in this study were fresh samples 
from HIV infected patients, OPD patients and prospec-
tive blood donors. Fresh sets of samples (EDTA-anti-
coagulated whole blood, and serum) were collected from 
295 patients (This includes participants with incomplete 
data).
Venous blood collected from each participant was 
divided into EDTA-anticoagulant and serum separator 
tubes labelled with the patient’s identification. The anti-
coagulant prevented the blood from clotting making it 
possible to obtain whole blood.
The serum separator tubes were centrifuged at 
3000  rpm for 15  min to obtain the serum samples. The 
whole blood samples were stored at refrigeration tem-
perature at 4  °C and the serum samples at −20  °C until 
used. Testing was done not more than 72 h after sample 
collection.
HIV antigen (p24)/antibody test
HIV Antigen (p24)/antibody tests were done by auto-
mation on Cobas E 411 analyzer using serum samples. 
Because the sample of choice for this analyzer was serum, 
whole blood samples could not be analyzed. All 295 
serum samples were analyzed to determine their HIV 
sero-status.
Cobas E 411
Cobas E 411 (Roche Diagnostics GmbH, Mannheim, 
Germany) is a fully automated immunoassay analyzer 
which uses electro-chem-iluminescence immunoas-
say (ECLIA) technology to detect HIV-1 and HIV-2 in 
human serum. The analyzer had sample loading cham-
bers, a touch-screen monitor and a printer. This study 
used Elecsys HIV combi PT (Roche Diagnostics GmbH, 
Mannheim, Germany) as reagents. This reagent is a 
fourth generation qualitative immunoassay for the deter-
mination of HIV-1 p24 antigens and antibodies to HIV-1, 
including group O, and HIV-2 in serum. Test results were 
produced within 30 min after loading samples.
Samples with cutoff index (COI) <0.9 were considered 
non-reactive (negative) and those with COI  ≥1.0 con-
sidered reactive (positive). There were no observed COI 
readings in the range ≥0.9 to <1.0 (borderline) among the 
samples, HIV RNA test was therefore not needed.
HIV antibody test
All HIV antibody tests were performed by applying whole 
blood or serum on First Response HIV-1-2 test kits.
First Response HIV‑1‑2 test kit
First Response HIV-1-2 (Premier Medical Corporation 
Ltd., Kachigam, India) kit is a rapid immuno-chroma-
tographic qualitative test for the detection of antibodies 
to HIV-1 and HIV-2 in whole blood, plasma or serum. 
The kit was packaged with a sample pipette and a sample 
buffer.
The kit had two test-band regions. Region “1” was pre-
coated with recombinant HIV-1 antigens (gp 41, includ-
ing group O and p24) and region “2” was pre-coated with 
recombinant HIV-2 antigen (gp36). These recombinant 
antigens were conjugated with colloidal gold particles. 
There was a region labelled “C”, the inbuilt control line 
which indicated successful antigen–antibody reaction.
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The results were interpreted according to the manufac-
turer’s instruction document. Red lines at both regions 
“1” and “C” meant HIV-1 infection and at regions “2” and 
“C” was indicative of HIV-2 infection.
Legend negative (single red band at control line). Posi-
tive (two red bands, one at 1 and the other at the control).
Classifying samples as HIV infected or non‑infected
We used ECLIA technology as the gold standard test 
in this study. The whole blood and serum samples were 
first tested on First Response HIV-1-2 test kits simulta-
neously. Both reactive and non-reactive samples were 
retested on Cobas E 411 analyzer. This enabled us to clas-
sify the samples as HIV infected and HIV non-infected. 
Samples with reactive results for both whole blood and 
serum on the test kit and reactive serum result on the 
analyzer were classified positive.
Samples with non-reactive results for both whole blood 
and serum on the test kit and non-reactive serum result 
on the analyzer were classified negative. For samples 
that produced results on the test kit which did not agree 
with the analyzer (discordant results), a decision was 
made after consultations with HIV diagnostic experts. A 
repeated test was done with the test kit. The two results 
(initial and repeated) were compared and the blood-
based specimen type (whole blood or serum) result that 
agreed with the analyzer was chosen as the final result for 
classification.
All patient test results and information were treated 
confidential and the study was approved by the Ethical 
Review Board of Ghana Health Service (approval number 
GHS-ERC: 06/02/15).
Data analysis
Data analyses were performed using the statistical soft-
ware, StataSE (version 13.1, StataCorp, Texas, USA). 
Variables were summarized as frequencies and percent-
ages with significant level at 0.05. Sensitivity, specificity, 
positive and negative predictive values were determined 
using cross-tables and standard formulas {(PPV  =  sen-
sitivity  ×  prevalence/sensitivity  ×  prevalence  +  (1−
prevalence)} and {(NPV =  specificity ×  1−prevalence)/
(1−sensitivity)  ×  prevalence  +  specificity  ×  (1−preva-
lence)}.
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